Samsung Bioepis reveals clinical trial results of SB3 at ASCO in U.S.

Published: 2018-06-04 16:26:00
Updated: 2018-06-04 18:49:45

Samsung Bioepis(CEO/President Han-Seung Ko) revealed the 1-year clinical trial result of SB3(Herceptin biosimilar, generic name: trastuzumab, European name: Ontruzant, Korean name: Samfenet), a breast cancer therapy.

The recently announced clinical trial result is the first 1-year tracking resul...


- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.

Original Korean

Most Read News

Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email:

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.